Fulminant course of a Trousseau syndrome

Summary

The Trousseau syndrome is a clinical challenge and can be multi-faceted and often fulminant. We report a clinical case of a patient who initially presented with a thrombophlebitis saltans in our outpatient clinic. The further clinical course was dramatic and rapidly progressive in arterial and venous thrombosis and possible paradoxical embolisms. In staging, there was an urgent suspicion of the presence of metastatic cervical carcinoma. With continued rapid clinical worsening with progressive reduction of vigilance in recurrent thromboembolic events, persistent anuria and progression of ischemic areas, it was decided not to continue with the medical treatment given the severe and complex disease pattern. In a synopsis of the clinic and the diagnostic apparatus, we diagnosed a Trousseau syndrome. The patient died 15 days after the first presentation in our angiological consultation. In atypical clinic with recurrent episodic or foudroyant thrombophlebitis, venous and arterial thrombosis or thromboembolisms should be thought of paraneoplastic events and a malignant underlying disease secured or excluded.

Keywords

Trousseau syndrome - thrombophlebitis saltans - thrombosis - paradoxical embolism - thromboembolic event - fulminant

• Literatur

• 1 Trousseau A. Plegmasia alba dolens. Clinique Medicale de l´Hotel-Dieu Paris 03: 654-712.
• 2 Lee AY. Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br J Haematol 2005; 128 (03) 291-302.
• 3 Carrier M. et al. Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations. Curr Oncol 2015; 22 (01) 49-59.
• 4 van Es N. et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica 2017; 102 (09) 1494-1501.
• 5 Elting LS. et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004; 164 (15) 1653-1661.
• 6 Blom JW. et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293 (06) 715-722.
• 7 Falanga A, Russo L, Milesi V. The coagulopathy of cancer. Curr Opin Hematol 2014; 21 (05) 423-429.
• 8 Dicke C, Langer F. Pathophysiology of Trousseau’s syndrome. Phlebologie 2018; 47 (01) 24-31.
• 9 Guzman-Uribe P, Vargas-Ruiz AG. Thrombosis in leukemia: incidence, causes, and practical management. Curr Oncol Rep 2015; 17 (05) 444.
• 10 Piccioli A. et al. Cancer and venous thromboembolism. Am Heart J 1996; 132 (04) 850-855.
• 11 Levitan N. et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78 (05) 285-291.
• 12 Gerotziafas GT. et al. Clinical studies with anticoagulants to improve survival in cancer patients. Pathophysiol Haemost Thromb 2008; 36 (3-4): 204-211.
• 13 Trujillo-Santos J. et al. Clinical outcome in patients with venous thromboembolism and hidden cancer: findings from the RIETE Registry. J Thromb Haemost 2008; 06 (02) 251-255.
• 14 Akl EA. et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2008; (01) Cd006649.
• 15 Lee AY. et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (02) 146-153.
• 16 Beyer-Westendorf J, Werth S. Neue Optionen in der Antikoagulation bei Therapie-refraktärem Trousseau-Syndrom. Phlebologie 2011; 40: 211-215.
• 17 Samlaska CP, James WD. Superficial thrombophlebitis. II. Secondary hypercoagulable states. J Am Acad Dermatol 1990; 23 (01) 1-18.
• 18 Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106 (08) 2710-2715.